Amgen reports positive data from Phase III trial of erenumab to treat episodic migraine

US-based Amgen has reported positive top-line data from its Phase III ARISE Study of erenumab for the treatment of   episodic migraine.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news